PDL BioPharma Company Profile (NASDAQ:PDLI)

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

PDL BioPharma declared that its Board of Directors has initiated a share buyback plan on Monday, September 25th 2017, which authorizes the company to buyback $25,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

PDL BioPharma, Inc. (NASDAQ:PDLI) posted its earnings results on Thursday, August, 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.17. The firm earned $143.80 million during the quarter, compared to the consensus estimate of $56.30 million. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The company's revenue was up 584.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. View PDL BioPharma's Earnings History.

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for PDL BioPharma.

2 analysts have issued 12 month target prices for PDL BioPharma's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate PDL BioPharma's share price to reach $4.00 in the next twelve months. View Analyst Ratings for PDL BioPharma.

Here are some recent quotes from research analysts about PDL BioPharma stock:

• 1. According to Zacks Investment Research, "PDL BioPharma’s earnings in the second quarter of 2017 surpassed estimates. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, wherein, it is making equity investments in product-focused companies. The company’s royalty agreement with oncology-focused company, ARIAD, is also encouraging. PDL BioPharma’s shares have outperformed the industry in a year. However, the company is heavily dependent on its partners for royalty revenues, which is hardly a risk-free strategy. We are also concerned about PDL BioPharma’s revenue stream in the futureas its growth prospects rely on the timing and ability to acquire new income-generating assets in order to provide recurring revenues." (8/16/2017)
• 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

PDL BioPharma saw a increase in short interest in September. As of September 15th, there was short interest totalling 19,901,835 shares, an increase of 9.7% from the August 31st total of 18,146,418 shares. Based on an average daily volume of 2,224,175 shares, the short-interest ratio is currently 8.9 days. Currently, 13.3% of the company's stock are short sold.

Some companies that are related to PDL BioPharma include Arena Pharmaceuticals (ARNA), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), Crispr Theraptc (CRSP), Abeona Therapeutics (ABEO), ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), BeyondSpring (BYSI), WAVE Life Sciences (WVE), Voyager Therapeutics (VYGR), Celyad SA (CYAD), Inovio Pharmaceuticals (INO) and Mesoblast Limited (MESO).

PDL BioPharma's management team includes the folowing people:

• Dominique Monnet, President
• John Peter McLaughlin, Chief Executive Officer, Director
• Peter S. Garcia, Chief Financial Officer, Vice President
• Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance
• Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary
• Danny Hart, Vice President - Business Development
• Harold E. Selick Ph.D., Lead Independent Director
• Paul R. Edick, Independent Director
• David W. Gryska, Independent Director
• Jody S. Lindell, Independent Director

PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Shell Asset Management Co. (0.16%) and Eqis Capital Management Inc. (0.14%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for PDL BioPharma.

PDL BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Shell Asset Management Co.. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PDL BioPharma stock can currently be purchased for approximately $3.50.